ORIC Pharmaceuticals Inc (NASDAQ:ORIC) price on Friday, June 13, fall -0.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.63.
A look at the stock’s price movement, the close in the last trading session was $9.67. Turning to its 52-week performance, $14.67 and $3.90 were the 52-week high and 52-week low respectively. Overall, ORIC moved 97.94% over the past month.
ORIC Pharmaceuticals Inc’s market cap currently stands at around $820.71 million, with investors looking forward to this quarter’s earnings report slated for in July.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend ORIC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ORIC’s current price about 24.80% and 57.22% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 73.19, while 7-day volatility ratio is 2.76% and 7.41% in the 30-day chart. Further, ORIC Pharmaceuticals Inc (ORIC) has a beta value of 1.49, and an average true range (ATR) of 0.76. Analysts have given the company’s stock an average 52-week price target of $12, forecast between a low of $12 and high of $12. Looking at the price targets, the low is -24.61% off current price level while to achieve the yearly target high, price needs to move -24.61%. Nonetheless, investors will most likely welcome a -24.61% jump to $12 which is the analysts’ median price.
If we refocus on ORIC Pharmaceuticals Inc (NASDAQ:ORIC), historical trading data shows that trading volumes averaged 1.15 million over the past 3 months. The company’s latest data on shares outstanding shows there are 71.08 million shares.
The 43.81% of ORIC Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 69.91% of the company’s shares. Current price change has pushed the stock 19.33% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ORIC stock continues to rise going into the next quarter.
